BCG047 / Biocytogen - LARVOL DELTA

BCG047, a novel heavy chain antibody-drug conjugate targeting FOLR1, demonstrates outstanding preclinical antitumor efficacy (AACR 2026) - "Elahere, an FRα-targeted ADC, improves progression-free survival in platinum-resistant ovarian cancer but is limited to patients with high FRα expression and poses safety concerns. These data suggest that BCG047 is a promising therapeutic strategy targeting FOLR1, with the potential to expand the patient population benefiting from this treatment, particularly in low FOLR1 expression settings. To enhance pharmacokinetics and improve efficacy, modifications to BCG047 aimed at achieving a prolonged half-life are currently underway for further preclinical development."

ADC • Late-breaking abstract • Preclinical • Oncology • Ovarian Cancer • Solid Tumor • FOLR1